Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens

Vaccine. 2006 Mar 24;24(14):2514-20. doi: 10.1016/j.vaccine.2005.12.025. Epub 2005 Dec 27.

Abstract

We estimated the effectiveness of abbreviated regimens of 7-valent pneumococcal conjugate vaccine (PCV7) based on serotyped cases of invasive pneumococcal disease (IPD) in children under 5 reported from 2001 to 2004 to two US surveillance programs. Vaccination regimens included in the analysis were 1 dose < 3 months old, 2 doses < 5 months old, 3 doses < 7 months old, full schedule (3 doses and a booster), 1 dose at 12-23 months, and 2 doses at 12-23 months. Vaccine effectiveness (VE) was calculated as (1-Mantel-Haenszel summary odds ratio in vaccinated children, as compared to unvaccinated children)x100% for each regimen, stratifying by year. Among 400 eligible cases, for vaccine-type IPD, VE was 90.5% for the full schedule, 76.6% for 3 doses < 7 months old, and 70.5% for 2 doses < 5 months old; 1 dose < 3 months provided no significant protection. No regimen provided significant protection against vaccine-related serotypes. Data for regimens begun at 12-23 months were inconclusive. These data support the use of the 2-dose and 3-dose infant PCV7 regimens when the full series cannot be delivered and detail the limitations of abbreviated dosing regimens.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Child, Preschool
  • Humans
  • Immunization Schedule*
  • Infant
  • Infant, Newborn
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage*
  • Vaccines, Conjugate / administration & dosage*
  • Vaccines, Conjugate / immunology

Substances

  • Pneumococcal Vaccines
  • Vaccines, Conjugate